{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hyperlipoproteinemia+Type+II",
    "query": {
      "condition": "Hyperlipoproteinemia Type II"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 140,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hyperlipoproteinemia+Type+II&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-22T20:56:46.819Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01588496",
      "title": "Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Homozygous Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 58,
      "start_date": "2012-04-05",
      "completion_date": "2014-01-31",
      "has_results": true,
      "last_update_posted_date": "2018-11-29",
      "last_synced_at": "2026-07-22T20:56:46.819Z",
      "location_count": 2,
      "location_summary": "New York, New York • Cincinnati, Ohio",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01588496"
    },
    {
      "nct_id": "NCT05142722",
      "title": "Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dyslipidemias",
        "High Cholesterol",
        "Hypercholesterolemia",
        "Familial Hypercholesterolemia",
        "Atherosclerotic Cardiovascular Disease"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Obicetrapib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2530,
      "start_date": "2021-12-15",
      "completion_date": "2024-09-26",
      "has_results": true,
      "last_update_posted_date": "2025-09-19",
      "last_synced_at": "2026-07-22T20:56:46.819Z",
      "location_count": 69,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Saraland, Alabama + 60 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Sheffield",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05142722"
    },
    {
      "nct_id": "NCT05284513",
      "title": "Collaborative Approach to Reach Everyone With Familial Hypercholesterolemia (CARE-FH)",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "FH diagnosis program",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Develop and implement tools for quality monitoring",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Develop educational materials",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Conduct educational outreach visits",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Intervene with clinicians and patients to enhance",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Behavioral (e.g., Psychotherapy, Lifestyle Counseling) Implementation strategy package: Identify and prepare champions Clinical lipid champions",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Audit and provide feedback",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Implementation strategy package: Stage implementation scale up",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Geisinger Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "26 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "26 Years and older"
      },
      "enrollment_count": 532,
      "start_date": "2022-09-09",
      "completion_date": "2027-01",
      "has_results": false,
      "last_update_posted_date": "2025-12-22",
      "last_synced_at": "2026-07-22T20:56:46.819Z",
      "location_count": 1,
      "location_summary": "Multiple Locations, Pennsylvania",
      "locations": [
        {
          "city": "Multiple Locations",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05284513"
    },
    {
      "nct_id": "NCT00116870",
      "title": "MARS - Monitored Atherosclerosis Regression Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Atherosclerosis",
        "Coronary Artery Disease"
      ],
      "interventions": [
        {
          "name": "lovastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "67 Years",
        "sex": "ALL",
        "summary": "21 Years to 67 Years"
      },
      "enrollment_count": 270,
      "start_date": "1985-06",
      "completion_date": "1992-02",
      "has_results": false,
      "last_update_posted_date": "2009-12-11",
      "last_synced_at": "2026-07-22T20:56:46.819Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00116870"
    },
    {
      "nct_id": "NCT02392559",
      "title": "Trial Assessing Efficacy, Safety and Tolerability of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition in Paediatric Subjects With Genetic Low-Density Lipoprotein (LDL) Disorders",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Heterozygous Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "10 Years to 17 Years"
      },
      "enrollment_count": 158,
      "start_date": "2016-03-24",
      "completion_date": "2019-11-25",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-07-22T20:56:46.819Z",
      "location_count": 12,
      "location_summary": "Farmington, Connecticut • Wilmington, Delaware • Iowa City, Iowa + 9 more",
      "locations": [
        {
          "city": "Farmington",
          "state": "Connecticut"
        },
        {
          "city": "Wilmington",
          "state": "Delaware"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Towson",
          "state": "Maryland"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02392559"
    },
    {
      "nct_id": "NCT06831162",
      "title": "Evaluating the Effectiveness of a Multi-level Health-Related Social Needs Initiative",
      "overall_status": "ENROLLING_BY_INVITATION",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Type 2 Diabetes",
        "Hypertension",
        "Hyperlipidemia",
        "Health-related Social Problems"
      ],
      "interventions": [
        {
          "name": "Multi-level HRSN initiative",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4809,
      "start_date": "2025-01-24",
      "completion_date": "2026-09-04",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-07-22T20:56:46.819Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06831162"
    },
    {
      "nct_id": "NCT02597127",
      "title": "Trial to Evaluate the Effect of ALN-PCSSC Treatment on Low Density Lipoprotein Cholesterol (LDL-C)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Atherosclerotic Cardiovascular Disease",
        "Familial Hypercholesterolemia",
        "Diabetes"
      ],
      "interventions": [
        {
          "name": "ALN-PCSSC",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The Medicines Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 501,
      "start_date": "2016-01",
      "completion_date": "2017-06-07",
      "has_results": true,
      "last_update_posted_date": "2019-05-17",
      "last_synced_at": "2026-07-22T20:56:46.819Z",
      "location_count": 8,
      "location_summary": "Jacksonville, Florida • Indianapolis, Indiana • New York, New York + 4 more",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02597127"
    },
    {
      "nct_id": "NCT02722408",
      "title": "Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesteremia"
      ],
      "interventions": [
        {
          "name": "Gemcabene",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NeuroBo Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2016-06",
      "completion_date": "2017-07",
      "has_results": true,
      "last_update_posted_date": "2020-06-25",
      "last_synced_at": "2026-07-22T20:56:46.819Z",
      "location_count": 1,
      "location_summary": "Beverly Hills, California",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02722408"
    },
    {
      "nct_id": "NCT00403091",
      "title": "Internet Intervention to Improve Rural Diabetes Care",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetes Mellitus Type 2"
      ],
      "interventions": [
        {
          "name": "Internet Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Control",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 205,
      "start_date": "2005-04",
      "completion_date": "2010-04",
      "has_results": false,
      "last_update_posted_date": "2010-08-11",
      "last_synced_at": "2026-07-22T20:56:46.819Z",
      "location_count": 2,
      "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tuscaloosa",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00403091"
    },
    {
      "nct_id": "NCT00079859",
      "title": "Implitapide in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) on Maximal Concurrent Lipid-Lowering Therapy",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Familial Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Implitapide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical Research Laboratories International",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 120,
      "start_date": "2003-10",
      "completion_date": "2005-04",
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-07-22T20:56:46.819Z",
      "location_count": 1,
      "location_summary": "Cincinnati, Ohio",
      "locations": [
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00079859"
    }
  ]
}